在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯免疫試劑盒
  4. Human Rho GDP-dissociation inhibitor 2(ARHGDIB) ELISA kit

Human Rho GDP-dissociation inhibitor 2(ARHGDIB) ELISA kit

  • 中文名稱：
    人Rho GDP解離抑制因子2(ARHGDIB)酶聯免疫試劑盒
  • 貨號：
    CSB-EL002038HU
  • 規格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產品詳情

  • 產品描述：
    人Rho GDP解離抑制因子2(ARHGDIB)酶聯免疫試劑盒（CSB-EL002038HU）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿、細胞裂解物樣本中的ARHGDIB含量。試劑盒檢測范圍為25 pg/mL-1600 pg/mL，適用于基礎研究中ARHGDIB蛋白表達水平的定量分析，例如細胞信號轉導機制探索、疾病模型構建或藥物干預效果評估等科研場景本品僅用于科研，不用于臨床診斷，產品具體參數及操作步驟詳見產品說明書。
  • 別名：
    Arhgdib ELISA Kit; D4 ELISA Kit; D4 GDP dissociation inhibitor ELISA Kit; GDIA 2 ELISA Kit; GDIA2 ELISA Kit; GDID 4 ELISA Kit; GDID4 ELISA Kit; GDIR2_HUMAN ELISA Kit; GDP dissociation inhibitor D4 ELISA Kit; LY GDI ELISA Kit; Ly-GDI ELISA Kit; LYGDI ELISA Kit; MGC108926 ELISA Kit; RAP1GN1 ELISA Kit; Rho GDI 2 ELISA Kit; Rho GDI beta ELISA Kit; Rho GDI2 ELISA Kit; Rho GDP dissociation inhibitor (GDI) beta ELISA Kit; Rho GDP dissociation inhibitor 2 ELISA Kit; Rho GDP dissociation inhibitor beta ELISA Kit; Rho GDP-dissociation inhibitor 2 ELISA Kit; Rho-GDI beta ELISA Kit; RhoGDI2 ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates, cell lysates
  • 檢測范圍：
    25 pg/mL-1600 pg/mL
  • 靈敏度：
    6.25 pg/mL
  • 反應時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領域：
    Signal Transduction
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%        
    Three samples of known concentration were tested twenty times on one plate to assess.    
    Inter-assay Precision (Precision between assays): CV%<10%        
    Three samples of known concentration were tested in twenty assays to assess.      
                   
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human ARHGDIB in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
    　 Sample Serum(n=4)    
    1:1 Average % 87    
    Range % 85-93    
    1:2 Average % 104    
    Range % 96-108    
    1:4 Average % 92    
    Range % 85-96    
    1:8 Average % 101    
    Range % 98-105    
  • 回收率：
    The recovery of human ARHGDIB spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
     
    Sample Type Average % Recovery Range    
    Serum (n=5) 92 88-96    
    EDTA plasma (n=4) 103 98-107    
                   
                   
  • 標準曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
     
    pg/ml OD1 OD2 Average Corrected    
    1600 2.921 2.844 2.883 2.711    
    800 2.334 2.241 2.288 2.116    
    400 1.534 1.491 1.513 1.341    
    200 0.887 0.867 0.877 0.705    
    100 0.596 0.581 0.589 0.417    
    50 0.370 0.362 0.366 0.194    
    25 0.238 0.234 0.236 0.064    
    0 0.173 0.171 0.172 　    
  • 數據處理：
  • 貨期：
    3-5 working days

產品評價

靶點詳情

  • 功能：
    Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. Regulates reorganization of the actin cytoskeleton mediated by Rho family members.
  • 基因功能參考文獻：
    1. RhoGDIbeta overexpression led to downregulation of miR-200c, whereas miR-200c was able directly to target 3'-UTR of jnk2mRNA and attenuated JNK2 protein translation, which resulted in attenuation of Sp1mRNA and protein expression in turn, inhibiting Sp1-dependent MMP-2 transcription. PMID: 28846829
    2. Binders to RhoGDI2 as a potential anti-cancer target have been first reported, and their weak interactions were depicted using NMR spectroscopy. PMID: 27721047
    3. Delta19RhoGDIbeta has an apoptosisindependent role in the phorbol 12myristate 13acetate induced differentiation of THP1 cells to macrophages. PMID: 28260067
    4. The caspase-3-cleaved RhoGDIbeta is a possible determinant to promote cancer spreading. PMID: 26919575
    5. Our interpretation of these contradictions is that truncation and/or mutation of RhoGDI2 perturbs its conformation to expose a site that adventitiously binds FLNA and is not a bona-fide interaction. PMID: 26707877
    6. Results show that RhoGDI2 suppresses bladder cancer metastatic colonization via negative regulation of RhoC activity, providing a rationale for the development of therapeutics that target RhoC signaling. PMID: 25516960
    7. These findings indicate that RhoGDI2 repressed the activity of Rac1 and may be involved in the rearrangement of cytoskeleton in lung cancer cells. PMID: 25562149
    8. Short hairpin RNA-mediated knockdown of RhoGDI2 induces the invasion and migration of lung cancer due to cross-talk with the PI3K/Akt pathway and MMP-9. PMID: 25266803
    9. RhoGDI2 overexpression is associated with tumor growth, metastasis, and chemoresistance in gastric cancer. PMID: 24721928
    10. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. PMID: 24788627
    11. RhoGDI2 inhibits trophoblast cell migration, and this function may involve suppression of RAC1 activation. PMID: 24554735
    12. 14-3-3sigma is a RhoGDI2-regulated gene that appears to be important for suppressing the chemoresistance of gastric cancer cells. PMID: 24185104
    13. These results suggest that RhoGDIbeta has mitotic functions, including regulation of cytokinesis and bipolar spindle formation PMID: 23232495
    14. Rictor regulates cell migration by suppressing RhoGDI2. PMID: 22777355
    15. RhoGDI2 becomes rapidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation. Conventional type PKCalpha is responsible for this phosphorylation. PMID: 22469974
    16. Expression of ARHGDIB variants 6a, 6b, and 6c appears to be restricted to cancer cells and normal placental tissue, suggesting that these variants possess cancer-specific functions. PMID: 23206989
    17. The ARHGDIB is a lymphoid-specific intrinsic negative regulator of HIV-1 replication that acts by simultaneously inhibiting RhoA and Rac1 functions. PMID: 21936715
    18. Results suggest that D4-GDI may function as a biphasic regulator of breast cancer progression and metastasis. PMID: 22674302
    19. We delineate the mechanism by which RhoGDI2 promotes gastric cancer cell invasion and chemoresistance. In total, 47 differential protein spots were identified; 33 were upregulated, and 14 were downregulated by RhoGDI2 overexpression. PMID: 22364609
    20. RhoGDI2 suppresses lung metastasis in mouse models by reducing the expression of isoforms V1 and V3 of the proteoglycan versican. RhoGDI2 suppressed metastasis by altering inflammation in the tumor microenvironment. PMID: 22406535
    21. Overexpression of RhoGDI2 correlates with tumor progression in colorectal carcinoma. PMID: 21861235
    22. activation of the Src family members and downstream signalling proteins are associated with a good prognosis in transitional cell carcinoma of the bladder, and activated Src has a positive relationship with RhoGD12. PMID: 22353809
    23. PLCgamma plays a key role in RhoGDI2-mediated cisplatin resistance and cell invasion in gastric cancer cells. PMID: 21986528
    24. identification of LyGDI as a binding partner of SHIP, associating inducibly with the SHIP/Grb2/Shc complex PMID: 21695085
    25. This study has revealed that Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and the HSP70/90 organizing protein have a critical role to play in resistance to cyclin-depedent kinases inhibitor. PMID: 21067243
    26. RhoGDI2 is likely to be involved in lung tumor malignancy and metastasis. PMID: 20596634
    27. High LyGDI serum levels are associated with ovarian cancer. PMID: 20375790
    28. RhoGDI2 is associated with c-Src in bladder tumors, where the expression of both is diminished as a function of stage. c-Src binds to and phosphorylates RhoGDI2 resulting in enhanced metastasis suppressive potency. Review. PMID: 20013033
    29. These data suggest that D4-GDI of Rho family GTPase may be regulated during apoptosis through the caspase-3 mediated cleavage of the GDI protein. PMID: 11989976
    30. Results demonstrate that modification of Rho guanine nucleotide dissociation inhibitor (GDI) 2 during apoptosis is often accompanied by their relocalisation between cellular compartments [Rho GDI 2 ] PMID: 12203895
    31. the interaction of Vav1 and Ly-GDI creates a fine tuning mechanism for the regulation of intracellular signaling pathways leading to NFAT stimulation PMID: 12386169
    32. RhoGDI2 has a role in progression of bladder cancer PMID: 15173088
    33. RhoGDI2 may be implicated in the progress of malignancy. PMID: 17487395
    34. One gene identified by microarray gene expression analysis, RhoGDI2, was tested and confirmed to be metastasis supressor gene; results from cells expressing RhoG-two molecular effectors of RhoGDI2 signaling were identified: endothelin-1 and Neuromedin U. PMID: 17826660
    35. Rho-GDI beta has two roles: one that suppresses tumor progression by inhibiting migration and the other that stimulates it by enhancing Cox-2 expression PMID: 18006811
    36. D4-GDI with two mutations (V68L & V69A) inhibited GDP dissociation from Rho in a dominant negative manner. It accelerates invasion via regulation of cytoskeletal machinery. PMID: 18037226
    37. Transgenic mice with T cell-specific expression display altered cellular immunity against cytozoic pathogens PMID: 18689726
    38. Overexpression of D4-GDI is associated with breast cancer. PMID: 19269969
    39. RhoGDI2 metastasis inhibition works through Rho GTPases but via a mechanism distinct from inhibition of membrane association. PMID: 19276387
    40. phosphorylation by Src enhances RhoGDI2 metastasis suppression and loss of Src relieves metastasis suppression in tumor cells that maintain RhoGDI2 expression. PMID: 19321744
    41. RhoGDI2 is involved in gastric tumor growth and metastasis, and that RhoGDI2 may be a useful marker for tumor progression of human gastric cancer. PMID: 19351766
    42. Results show that the established nerve invasion model and the consensus signature of perineural invasion could be instrumental in the identification of novel therapeutic targets of pancreatic cancer as exemplified by KIF14 and ARHGDIbeta. PMID: 19509238

    顯示更多

    收起更多

  • 亞細胞定位：
    Cytoplasm, cytosol.
  • 蛋白家族：
    Rho GDI family
  • 組織特異性：
    Detected in bone marrow, thymus and spleen.
  • 數據庫鏈接：

    HGNC: 679

    OMIM: 602843

    KEGG: hsa:397

    STRING: 9606.ENSP00000228945

    UniGene: Hs.504877



主站蜘蛛池模板： 少妇人妻偷人精品视频| 四虎亚洲精品成人a在线观看| 中年人妻丰满av无码久久不卡| 午夜三级a三级三点| 色夜码无码av网站| 亚洲精品无码国产片| 欧美又大粗又爽又黄大片视频| 欧美性猛交xxxx乱大交丰满| 亚洲中文字幕aⅴ无码天堂| 在线资源天堂www| 久久国产福利播放| 韩国三级中文字幕hd| 艳妇乳肉豪妇荡乳av无码福利| 无码人妻精品一区二区三区夜夜嗨| 在线看片免费人成视频影院看| 午夜精品影视国产一区在线麻豆 | 国产偷人爽久久久久久老妇app| 国产精品人妻| 182tv午夜福利在线地址二| 欧美亚洲另类自拍丝袜| 午夜天堂av天堂久久久| 中文字幕一区二区三区日韩精品 | 色偷偷色噜噜狠狠网站久久 | 国产欧美一区二区精品性色| 久久人人做人人妻人人玩精品hd| 欧美亚洲人成网站在线观看| 欧美日韩中文在线字幕视频| 内射人妻少妇无码一本一道 | 18禁裸乳无遮挡啪啪无码免费| 中文字幕av伊人av无码av| 久久99亚洲精品久久久久| 日本无码人妻一区二区色欲| 欧美偷窥清纯综合图区| 欧美丰满少妇xxxx性| 99久久无色码中文字幕人妻蜜柚| 中文字幕一区二区三区久久网站| 国外亚洲成av人片在线观看| 亚洲va久久久噜噜噜久久狠狠| av无码一区二区二三区1区6区| 末成年女av片一区二区| 免费看少妇作爱视频|